
zzso represents a new zzso medication used as an adjunct to a zzso diet and increased physical activity treatment plan for chronic weight management in adult patients with an initial body mass index zzso 30 zzso 2 or in adult patients with an initial body mass index zzso 27 zzso 2 who have zzso 1 zzso condition associated with weight zzso hypertension, zzso or type 2 diabetes zzso In 2012, zzso became the first obesity treatment medication to gain US Food and Drug Administration zzso approval since zzso zzso is a centrally acting, selective zzso C zzso zzso full zzso that is associated with increased zzso and decreased food consumption in zzso The selectivity of zzso for zzso receptors should reduce patient risk for the serious adverse complications that are associated with zzso zzso zzso therapies, such as cardiac zzso and pulmonary zzso The safety and efficacy of zzso (10 zzso twice zzso for zzso 52 weeks has been evaluated in 3 separate Phase 3 zzso The primary outcome of patient weight loss in the 3 trials satisfied the zzso zzso benchmark but patient outcomes in the trials failed to achieve the zzso mean benchmark of patient weight zzso Secondary patient outcomes after zzso therapy were zzso zzso appears to be well tolerated in patients and the most common adverse events reported did not include serious zzso The zzso of zzso zzso in patients after 1 year of treatment was low and zzso but the statistical analysis of this safety zzso was limited due to the small size of the study populations and high patient dropout zzso zzso zzso surveillance of patients taking zzso is zzso 

